🔗 Share this article

A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Drug Gaining Traction Online

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Viewers are encouraged to message these accounts directly for source information, while also obtaining discount codes.

Active Commerce on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where groups with numerous of participants share comparison images, administration instructions and assertions of next-day UK delivery. Sellers market the substance there before directing customers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an experimental injection created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Professionals Voice Concerns

However, doctors and chemists have cautions that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could result in users administering products of unknown origin.

Some experts stated the popularity for retatrutide could be connected to the rising price of licensed weight loss treatments such as Mounjaro.

Regulatory Status and Implementation

Selling retatrutide on TikTok or Telegram is illegal in the UK, as it is an unapproved drug that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach medicines, advertising, and customer laws, potentially leading to fines, prosecution or imprisonment.

Platform Response and Content Elimination

According to the social media company, the platform has taken down problematic content and banned associated hashtags and query recommendations. The company stated it was dedicated to keeping the platform secure and investing in enhancing compliance measures.

Digital Trading Operations

Investigations also found groups with up to 9,000 participants marketing retatrutide using Telegram's built-in search feature, which functions like a online catalog. Entering “retatrutide” immediately displays channels with numerous of members, filled with photos of weight loss, positive testimonials and detailed instructions for mixing or injecting at home.

Within moments of entering one community, a seller posted contact information, where most transactions occur. The vendor provided an guidebook and promised shipping within two days. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one asked about body mass, health issues or previous experience.

Product Information and Pricing

Within these communities, messages show black plastic packages with postal service labels, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors typically sold at £160 for 20 milligrams. When asked how much time a pen should be used, vendors give conflicting answers ranging from a several days to “depends on your body”.

Platform Oversight and Safety Measures

A representative for Telegram stated it regularly monitored dangerous content on its service including content that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they cannot confirm. Although the research behind retatrutide is valid, these digital versions may not include what they claim,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor linked the increase in demand to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With prices rising, patients are using online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her team has previously encountered patients injured by personal administration from unconfirmed suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Producer Position

A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority globally. “Consequently at this time no one can market [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a company investigational substance not yet authorized … may subject patients to possibly significant medical dangers”.